Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 64 for “"Combretastatin"”.

  1. Synthesis, characterization, and biological evaluation of bioreductively activatable prodrug conjugates (BAPCs) of phenstatin, KGP18, OXi6196, combretastatin A-1, and combretastatin A-4.

    … to enhanced tumor necrosis. Phenstatin, OXi6196, combretastatin A-1(CA1), combretastatin A-4 (CA4), and KGP18 are promising anticancer agents for development as BAPCs. These compounds are effective inhibitors of tubulin assembly and demonstrate potent activity in vitro against human cancer cell …

    baylor Repository record for Synthesis, characterization, and biological evaluation of bioreductively activatable prodrug conjugates (BAPCs) of phenstatin, KGP18, OXi6196, combretastatin A-1, and combretastatin A-4. (opens in a new tab)

  2. Neue Synthesen von Oxa[1.n]metaparacyclophanen der Combretastatin D Familie

    … aus den Vorarbeiten zur Totalsynthese von (−)-Combretastatin D-1 am Arbeitskreis Schobert. Der Schlüsselschritt der Synthese ist der Ringschluss. Dieser sollte durch eine intramolekulare Addition-Wittig- Reaktion der Cyclisierungsvorstufe mit Ketenylidentriphenylphosphoran zum Makrolacton …

    bayreuth Repository record for Neue Synthesen von Oxa[1.n]metaparacyclophanen der Combretastatin D Familie (opens in a new tab)

  3. Two-Photon Microscopy of E-Combretastatin uptake and activation in live mammalian cells

    … modalities to combat this disease is important.Combretastatins are powerful anticancer drugs that are being evaluated in phase I/II clinicaltrials. Combretastatins act by binding to p-tubulin, preventing microtubule assembly andinhibiting angiogenesis in developing tumours. Most widely studied …

    salford Download PDF for Two-Photon Microscopy of E-Combretastatin uptake and activation in live mammalian cells (opens in a new tab)

  4. Synthesis and evaluation of tetramethoxy stilbenes related to combretastatin A-4 as potential anticancer agents

    … display less toxicity (Ali et al., 2012). Combretastatins are known to have cytotoxic activity against cancer cells with minimal side effects (Kretzschmann & Fürst, 2013). Derivatives with improved activity and less detrimental side effects are required. The different activities of …

    salford Download PDF for Synthesis and evaluation of tetramethoxy stilbenes related to combretastatin A-4 as potential anticancer agents (opens in a new tab)

  5. Synthesis and Biological Evaluation of Novel Resveratrol and Combretastatin A4 Derivatives as Potent Anti-Cancer Agents

    … for treatment of obesity and/or drug dependency. Combretastatin A4 (CA-4) is one of the most potent antiangiogenic and antimitotic agents of natural origin. However, CA-4 suffers from chemical instability due to cis-trans isomerism in solution. To circumvent this problem, we have developed a …

    uky-thes Repository record for Synthesis and Biological Evaluation of Novel Resveratrol and Combretastatin A4 Derivatives as Potent Anti-Cancer Agents (opens in a new tab)

  6. Synthesis of protected amino thymidines and new thiol derivatives of the vascular targeting agent combretastatin A-4.

    … analogues of the vascular targeting agent (VTA) Combretastatin A4 (CA4) were also synthesized. Vascular targeting agents are a class of anticancer compounds made to target and restrict tumor neovasculature. Disruption of these new tumor-associated capillaries prevents the blood flow necessary to …

    baylor Repository record for Synthesis of protected amino thymidines and new thiol derivatives of the vascular targeting agent combretastatin A-4. (opens in a new tab)

  7. Biochemical studies of targeted and bimodal analogues of the natural anticancer compounds combretastatin A-4 and illudin M

    This thesis presents a study on novel chemotherapeutics based on naturally designed scaffolds. The cytotoxicity of promising pharmaceutical compounds was tested on various cells of neural and/or cancerous origin, monitoring their specificity, re-growth retardation and mechanism of apoptosis …

    bayreuth Repository record for Biochemical studies of targeted and bimodal analogues of the natural anticancer compounds combretastatin A-4 and illudin M (opens in a new tab)

  8. Design, synthesis and biological evaluation of novel serotonin reuptake inhibitors and novel derivatives of a nitrogen-containing combretastatin analog.

    Depression is a common and serious illness that affects one out of every ten Americans each year. Since the 1980's, selective serotonin reuptake inhibitors (SSRIs) have been the pharmaceuticals of choice for the treatment of depression and related disorders. Despite their indisputable efficacy, …

    baylor Repository record for Design, synthesis and biological evaluation of novel serotonin reuptake inhibitors and novel derivatives of a nitrogen-containing combretastatin analog. (opens in a new tab)

  9. Structure-activity relationships and thermodynamics of combretastatin A-4 and A-1 derivatives as potential inhibitors of tubulin polymerization.

    … we have determined the effect of more than 78 combretastatin A-4 and A-1 analogs on tubulin polymerization. Combretastatin analogs with substitutions in both the trimethoxyphenyl and phenolic rings were analyzed. These included bromo, chloro, fluoro, mono and di-nitro, di-amino and di-amino …

    baylor Repository record for Structure-activity relationships and thermodynamics of combretastatin A-4 and A-1 derivatives as potential inhibitors of tubulin polymerization. (opens in a new tab)

  10. Design, synthesis, and biological evaluation of dihydronaphthalene and chalcone-based anticancer agents inspired by the natural product combretastatin A-4.

    … results in tumor necrosis. The natural product combretastatin A-4 (CA4) is widely accepted as the gold standard of VDAs and the clinical success of its corresponding water-soluble phosphate prodrug salt CA4P has inspired the development of a myriad of analogues and derivatives. Two …

    baylor Repository record for Design, synthesis, and biological evaluation of dihydronaphthalene and chalcone-based anticancer agents inspired by the natural product combretastatin A-4. (opens in a new tab)

  11. ΟΛΙΚΗ ΑΣΥΜΜΕΤΡΗ ΣΥΝΘΕΣΗ ΔΡΑΣΤΙΚΩΝ ΣΥΣΤΑΤΙΚΩΝ ΤΟΥ ΦΥΤΟΥ COMBRETUM CAFFRUM ΚΑΙ ΑΝΑΛΟΓΩΝ ΜΑΚΡΟΛΑΚΤΟΝΩΝ ΜΕ ΑΝΤΙΚΑΡΚΙΝΙΚΕΣ ΙΔΙΟΤΗΤΕΣ

    IN THIS PH.D. THESIS TOTAL SYNTHESIS OF COMBRETASTATINS D IS PRESENTED. COMBRETASTATINES D ARE COMPONENTS OF COMBRETUM CAFFRUM, A FOLK MEDICAL PLANT OF SOUTH AFRICA AND SHOW CYTOTOXIC ACTIVITY. COMBRETASTATIN D-2 WAS SYNTHESIZED VIA A10 STEP SEQUENCE. THE MAIN STEPS ARE: WITTIG REACTIONS, ULLMANN …

    greece Repository record for ΟΛΙΚΗ ΑΣΥΜΜΕΤΡΗ ΣΥΝΘΕΣΗ ΔΡΑΣΤΙΚΩΝ ΣΥΣΤΑΤΙΚΩΝ ΤΟΥ ΦΥΤΟΥ COMBRETUM CAFFRUM ΚΑΙ ΑΝΑΛΟΓΩΝ ΜΑΚΡΟΛΑΚΤΟΝΩΝ ΜΕ ΑΝΤΙΚΑΡΚΙΝΙΚΕΣ ΙΔΙΟΤΗΤΕΣ (opens in a new tab)

  12. Design, synthesis and evaluation of di-nitrogen derivatives of combretastatin and novel cruzain inhibiting compounds for the treatment of Chagas disease.

    … tumor microenvironment. The continued success of combretastatin A4 and combretastatin A1 in human clinical development indicate the importance of preparing new synthetic analogs to further understand the role of these anti-mitotic agents. Accordingly, a small library of eleven functionalized …

    baylor Repository record for Design, synthesis and evaluation of di-nitrogen derivatives of combretastatin and novel cruzain inhibiting compounds for the treatment of Chagas disease. (opens in a new tab)

  13. Discovery and development of unique small molecule chromene based ligands and combretastatin analogs as potential second generation vascular disrupting agents towards cancer chemotherapy.

    … active investigation and lead compounds, like combretastatin-A4P, combretastatin-A1P, AC7700 and ZD6126 are in clinical trials for the treatment of cancer, here in the US and in the UK. In this study, a small library of thirteen unique chromenes have been synthesized and evaluated for their …

    baylor Repository record for Discovery and development of unique small molecule chromene based ligands and combretastatin analogs as potential second generation vascular disrupting agents towards cancer chemotherapy. (opens in a new tab)

  14. Design and synthesis of dihydronaphthalene vascular disrupting agents and indolequinone-based bioreductives.

    … show great promise. The naturally occurring combretastatins, especially combretastatin A-4 (CA4) and combretastatin A-1 (CA1), in suitable prodrug form, have proven to be highly effective VDAs. In this study, efforts were directed towards the synthesis of two combretastatin analogs bearing …

    baylor Repository record for Design and synthesis of dihydronaphthalene vascular disrupting agents and indolequinone-based bioreductives. (opens in a new tab)

  15. Synthesis and evaluation of novel heterocyclic compounds as anticancer agents

    … and tubulin sulfhydryl binding sites. Combretastatin A-4 is one of the mostpotent natural products targeting tubulin and prevents microtubule polymerisation thatleads to mitosis arrest and apoptosis in endothelial cells. Moreover, it can cause selectivevascular shutdown for the tumour …

    salford Download PDF for Synthesis and evaluation of novel heterocyclic compounds as anticancer agents (opens in a new tab)

  16. Design and synthesis of combretastatin A-1 analogs, small molecule vascular disrupting agents, and bioreductive triggers as potential therapeutic agents for the treatment of cancer.

    … for the treatment of cancer. VDAs, such as combretastatin A1 phosphate (CA1P, Oxi4503) and combretastatin A4 phosphate (CA4P, ZybrestatTM, fosbretabulin), after undergoing phosphate cleavage by non-specific phosphatase enzymes, selectively bind to the colchicine site on tubulin, disrupting …

    baylor Repository record for Design and synthesis of combretastatin A-1 analogs, small molecule vascular disrupting agents, and bioreductive triggers as potential therapeutic agents for the treatment of cancer. (opens in a new tab)

  17. Design, synthesis, and biological evaluation of tumor-selective vascular disrupting agents, water-soluble amino acid prodrug conjugates, and bioreductively activatable prodrug conjugates targeting tumor hypoxia.

    … therapeutic option for cancer treatment. Combretastatin A-1 (CA1) and combretastatin A-4 (CA4) are members of a family of inhibitors of tubulin polymerization which functions as tumor-selective vascular disrupting agents (VDAs). The success of clinical trials involving the phosphate …

    baylor Repository record for Design, synthesis, and biological evaluation of tumor-selective vascular disrupting agents, water-soluble amino acid prodrug conjugates, and bioreductively activatable prodrug conjugates targeting tumor hypoxia. (opens in a new tab)

  18. Design, synthesis, and biological evaluation of benzosuberene and chalcone-based tubulin binding agents inspired by the natural product combretastatin A-4 and prodrugs targeting tumor-associated hypoxia.

    … and eventually necrosis. The natural products, combretastatin A-4 (CA4) and combretastatin A-1 (CA1) are potent VDAs that have inspired significant structure activity relationship (SAR) campaigns to design analogues that impart enhanced efficacy of vascular shutdown and cytotoxicity leading to …

    baylor Repository record for Design, synthesis, and biological evaluation of benzosuberene and chalcone-based tubulin binding agents inspired by the natural product combretastatin A-4 and prodrugs targeting tumor-associated hypoxia. (opens in a new tab) Embargoed until 2026-12-15

Page 1 of 4